Oxford BioTherapeutics has appointed Bernd Seizinger as Chairman, and and Jean-Pierre Bizzari, M.D. as a non-executive director, calling it a significant strengthening of its oncology focused board.
The new arrivals will join Glenn Begley, Shawn Tomasello, Tom Bradley and Christian Rohlff.
Bernd Seizinger brings over 20 years of industry experience from likes of Bristol-Myers Squibb, GPC Biotech where he was the CEO and President, and he was also Chairman of Aprea, Opsona and CryptoMedix.
Dr Seizinger said: “Oxford BioTherapeutics has considerable momentum, progressing an excitingimmuno-oncology and ADC pipeline, as well as our fully-funded partnered pipeline. Our corporate evolution is now driven by ourbroad-scale ability to discover and translate novel targets into biologics drug candidates with compelling in vivo anti-tumor activity.”
Jean-Pierre Bizzari brings 32 years’ experience including as EVP and Group Head of Clinical Oncology at Celgene until 2015, and Sanofi Aventis prior to that, and has directed the clinical development and approval of a number of important anti-cancer medicines.